Prefilled Syringes

Two complementary pipeline products added through a licensing agreement with France-based pharmaceutical company Laboratoire Aguettant

Fedsyra™ (ephedrine)

Pre-filled, ready-to-use syringes of commonly used products for acute care

Pre-filled, ready-to-use ephedrine and phenylephrine syringes combined market opportunity is estimated at over $100 million

PFS-02 (phenylephrine)

Minimal expected cost to get the products through NDA submissions and potential approval

NDA submission for ephedrine expected in 2023 and phenylephrine expected in 2024

Approved and marketed products in Europe and other regions outside the U.S.